Author

L. L. Gluud

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Pathology· 1 Physiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Approach:experimental assay· 2 Organism:human· 2 Assay:proteomics· 2 Assay:bulk RNA-seq· 1 Research Focus:drug response / drug discovery· 1 Assay:imaging· 1

Frequent Co-Authors

A. Billeschou Bomholt· 1 shared A. Hald· 1 shared B. M. Viuff· 1 shared C. Dall Johansen· 1 shared C. J. Weston· 1 shared C. Mehlin Soerensen· 1 shared C. Oerskov· 1 shared E. D. Galsgaard· 1 shared

Activity by Year

2021-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperPhysiology

A. Billeschou Bomholt

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Evaluation of Gremlin-1 as a therapeutic target in metabolic dysfunction-associated steatohepatitis

P. Horn, J. Norlin, K. Almholt, B. M. Viuff, E. D. Galsgaard, A. Hald, F. Zosel, H. Demuth, S. Poulsen, P. L. Norby, M. G. Rasch, M. Vyberg, M. P. Werge, L. L. Gluud, M. R. Rink, , P. N. Newsome

This study evaluates Gremlin-1 as a therapeutic target in MASH fibrosis, finding it upregulated but not amenable to targeting due to its restricted expression and lack of effect on fibrogenesis.

bioRxiv · Jan 3, 2024Pathology

Evaluation of Commercially Available Glucagon Receptor Antibodies and Glucagon Receptor Expression

A. Billeschou Bomholt, C. Dall Johansen, S. A. S. Kjeldsen, K. Douglas Galsgaard, J. Bager Christensen, M. Winther-Soerensen, R. Serizawa, M. Hornum, E. Porrini, J. Pedersen, C. Oerskov, L. L. Gluud, C. Mehlin Soerensen, J. J. Holst, R. Albrechtsen, N. J. Wewer Albrechtsen

This study evaluates commercially available glucagon receptor antibodies and identifies a specific antibody for GCGR localization, confirming liver and kidney as primary glucagon targets.

bioRxiv · Dec 21, 2021Physiology